Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Payables (2020 - 2026)

BioScience Health Innovations has reported Payables over the past 7 years, most recently at $467189.0 for Q1 2026.

  • Quarterly Payables rose 2746.11% to $467189.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $467189.0 through Mar 2026, up 2746.11% year-over-year, with the annual reading at $6274.0 for FY2025, 23.73% down from the prior year.
  • Payables was $467189.0 for Q1 2026 at BioScience Health Innovations, up from $6274.0 in the prior quarter.
  • Over five years, Payables peaked at $467189.0 in Q1 2026 and troughed at $901.0 in Q2 2023.
  • The 5-year median for Payables is $8226.0 (2024), against an average of $35667.0.
  • Year-over-year, Payables tumbled 73.62% in 2022 and then skyrocketed 2746.11% in 2026.
  • A 5-year view of Payables shows it stood at $2867.0 in 2022, then soared by 167.7% to $7675.0 in 2023, then grew by 7.18% to $8226.0 in 2024, then dropped by 23.73% to $6274.0 in 2025, then soared by 7346.43% to $467189.0 in 2026.
  • Per Business Quant, the three most recent readings for BHIC's Payables are $467189.0 (Q1 2026), $6274.0 (Q4 2025), and $10165.0 (Q3 2025).